Rhythm Pharmaceuticals, Inc. (RYTM) News

Rhythm Pharmaceuticals, Inc. (RYTM): $6.89

0.14 (+2.07%)

POWR Rating

Component Grades













Filter RYTM News Items

RYTM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RYTM News Highlights

  • RYTM's 30 day story count now stands at 4.
  • Over the past 2 days, the trend for RYTM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • RARE are the most mentioned tickers in articles about RYTM.

Latest RYTM News From Around the Web

Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns Remain

No summary available.

Seeking Alpha | January 15, 2022

Dosing underway in Rhythm Pharma''s setmelanotide trial for rare genetic disease of obesity

Rhythm Pharmaceuticals <> announces the first patient has been dosed with setmelanotide, the companys melanocortin-4 receptor (MC4R) agonist, in Phase 2 DAYBREAK clinical trial

Seeking Alpha | January 13, 2022

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity ---- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes ---- First patient also dosed in Phase 3 switch trial evaluating a weekly formulation of setmelanotide -- BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to tra

Yahoo | January 13, 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Monday . The stock had previously closed at $9.64, but opened at $10.16. Rhythm Pharmaceuticals shares last traded at $10.16, with a volume of 6 shares trading hands. A number of research analysts have commented on the stock. The Goldman Sachs Group upgraded shares of [] The post Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64 appeared first on ETF Daily News .

ETF Daily News | December 22, 2021

Zacks: Analysts Anticipate Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to Announce -$1.00 EPS

Wall Street analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to announce earnings per share (EPS) of ($1.00) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Rhythm Pharmaceuticals earnings, with estimates ranging from ($1.08) to ($0.91). Rhythm Pharmaceuticals reported earnings per share of ($0.79) during the same quarter last year, []

Transcript Daily | December 12, 2021

Rhythm Pharmaceuticals (NASDAQ:RYTM) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) in a report issued on Wednesday morning, Analyst Price Targets reports. The brokerage issued an overweight rating and a $30.00 target price on the stock. Other analysts have also issued research reports about the stock. Morgan Stanley lowered shares of Rhythm Pharmaceuticals from []

Dakota Financial News | December 12, 2021

Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ...

Investment company Penn Series Small Cap Growth Fund (Current Portfolio) buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Rogers Corp, CarParts.com Inc, sells Guidewire Software Inc, Alarm.com Holdings Inc, Standex International Corp, H.B.

Yahoo | December 11, 2021

Investors in Rhythm Pharmaceuticals (NASDAQ:RYTM) have unfortunately lost 65% over the last year

Taking the occasional loss comes part and parcel with investing on the stock market. Anyone who held Rhythm...

Yahoo | December 10, 2021

Wells Fargo Bullish on These 2 Stocks for 90% Upside (Or More)

Recent weeks have given us some hints that change may be in store. The Federal Reserve has indicated that it just may possibly be ready to start moving towards an end of its long-held easy money policy, and the Omicron variant of COVID is promising who-knows-what in the ongoing global health crisis. But the stock markets trending back up, after a late-November pullback. That turn upward would appear to have some historical backing.

Michael Marcus on TipRanks | December 9, 2021

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of Hold from Brokerages

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) have received a consensus recommendation of Hold from the eight ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 [] The post Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of Hold from Brokerages appeared first on ETF Daily News .

ETF Daily News | December 9, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5943 seconds.